Pharmaceutical composition for treating tumor
Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
1. A method for treating a tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof, wherein the PD-1 antagonist is an anti-PD-1 antibody, and wherein the tumor is selected from the group consisting of breast cancer, colorectal cancer, and kidney cancer.
2. The method according to claim 1 , wherein the liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and the PD-1 antagonist are administered simultaneously.
3. The method according to claim 1 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
4. The method according to claim 1 , wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, sintilimab, and toripalimab.
5. The method according to claim 1 , wherein the tumor is breast cancer.
6. The method according to claim 1 , wherein the liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and the PD-1 antagonist are administered separately.
7. The method according to claim 4 , wherein the tumor is breast cancer.
8. The method according to claim 1 , wherein the tumor is colorectal cancer.
9. The method according to claim 4 , wherein the tumor is colorectal cancer.
10. The method according to claim 1 , wherein the tumor is kidney cancer.
11. The method according to claim 4 , wherein the tumor is kidney cancer.
12. The method according to claim 5 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
13. The method according to claim 7 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
14. The method according to claim 8 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
15. The method according to claim 9 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
16. The method according to claim 10 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.
17. The method according to claim 11 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.